Cat. No.
MABL-3918
Application
IP, WB, ELISA, FC, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
DH8.3
From
Recombinant Antibody
Specificity
This antibody is specific for ΔEGFR (EGFR type III), a truncated form of the epidermal growth factor receptor that is commonly associated with cancer cells, especially glioblastoma cells. ΔEGFR lacks exons 2–7 of the external domain. This antibody does not cross-react with full-length EGFR.
Alternative Names
ΔEGFR; Epidermal growth factor receptor; EC:2.7.10.1; Proto-oncogene c- ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1
UniProt
P00533
Immunogen
The original monoclonal antibody was generated by immunizing HuMAb mice with alternating A431 cells and purified EGFR administration.
Application Notes
This antibody blocks the binding of EGF and TGF-α to the EGFR. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R- overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Flow cytometry was used to analyze the binding of mAb 2F8 to EGFR overexpressing A431 cells. mAb 2F8 was found to bind to membrane-associated EGF-R with an EC50 of approximately 1 µg/ml (7 nM). The ability of mAb 2F8 to block ligand-induced receptor phosphorylation was determined using immunoblotting. ELISA was used to determine whether mAb 2F8 had a functional C1q binding cite (Bleeker et al., 2004). Phase I/II clinical trials and pharmacokinetic studies in patients with advanced squamous cell carcinoma of the head and neck revealsed that 2F8/HuMax-EGFR can be safely administered in doses upto 8 mg/kg (Bastholt et al., 2007) Antibody 2F8 binds the domain III of the EGFR and locks it into a very compact and inactice conformation.
Antibody First Published
Bleeker et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. (2004); 173(7):4699-707. PMID:15383606
Note on publication
Describes the characterization of this antibody.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
